Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer

Eleonora Farina, Jenny Capuccini, Gabriella Macchia, Luciana Caravatta, Nam P. Nguyen, Silvia Cammelli, Andrea Farioli, Giuseppe Zanirato Rambaldi, Savino Cilla, Tigeneh Wondemagegnhu, A. F.M.Kamal Uddin, Mostafà Aziz Sumon, Domenico Genovesi, Milly Buwenge, Francesco Cellini, Vincenzo Valentini, Francesco Deodato, Alessio G. Morganti

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site. Patients and Methods: A phase I trial in four dose-escalation steps was planned: total dose ranged between 14 and 20 Gy in a total of four fractions administered twice a day. The dose-limiting toxicity (DLT) was determined as grade 3 or more toxicity occurring during treatment. The MTD obtained was used to plan a phase II trial. Results: A total of 48 patients were treated. In the phase I trial, the 20 Gy dose level was determined to be the MTD. In the phase II trial, the palliative response rate was 82.7%, with a median duration of palliation of 3 months. Conclusion: Short-course accelerated radiotherapy was well tolerated and effective for palliation. These findings may help design future prospective randomized studies.

Original languageEnglish
Pages (from-to)2409-2414
Number of pages6
JournalAnticancer Research
Volume38
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Maximum Tolerated Dose
Head and Neck Neoplasms
Radiotherapy
Prospective Studies
Neoplasm Metastasis
Therapeutics

Keywords

  • Head
  • Neck cancer
  • Pain
  • Palliative care
  • Quality of life
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Farina, E., Capuccini, J., Macchia, G., Caravatta, L., Nguyen, N. P., Cammelli, S., ... Morganti, A. G. (2018). Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer. Anticancer Research, 38(4), 2409-2414. https://doi.org/10.21873/anticanres.12491

Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer. / Farina, Eleonora; Capuccini, Jenny; Macchia, Gabriella; Caravatta, Luciana; Nguyen, Nam P.; Cammelli, Silvia; Farioli, Andrea; Rambaldi, Giuseppe Zanirato; Cilla, Savino; Wondemagegnhu, Tigeneh; Uddin, A. F.M.Kamal; Sumon, Mostafà Aziz; Genovesi, Domenico; Buwenge, Milly; Cellini, Francesco; Valentini, Vincenzo; Deodato, Francesco; Morganti, Alessio G.

In: Anticancer Research, Vol. 38, No. 4, 01.04.2018, p. 2409-2414.

Research output: Contribution to journalArticle

Farina, E, Capuccini, J, Macchia, G, Caravatta, L, Nguyen, NP, Cammelli, S, Farioli, A, Rambaldi, GZ, Cilla, S, Wondemagegnhu, T, Uddin, AFMK, Sumon, MA, Genovesi, D, Buwenge, M, Cellini, F, Valentini, V, Deodato, F & Morganti, AG 2018, 'Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer', Anticancer Research, vol. 38, no. 4, pp. 2409-2414. https://doi.org/10.21873/anticanres.12491
Farina, Eleonora ; Capuccini, Jenny ; Macchia, Gabriella ; Caravatta, Luciana ; Nguyen, Nam P. ; Cammelli, Silvia ; Farioli, Andrea ; Rambaldi, Giuseppe Zanirato ; Cilla, Savino ; Wondemagegnhu, Tigeneh ; Uddin, A. F.M.Kamal ; Sumon, Mostafà Aziz ; Genovesi, Domenico ; Buwenge, Milly ; Cellini, Francesco ; Valentini, Vincenzo ; Deodato, Francesco ; Morganti, Alessio G. / Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer. In: Anticancer Research. 2018 ; Vol. 38, No. 4. pp. 2409-2414.
@article{10a5d129b3344a33a4972ac1e0f2c4d0,
title = "Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer",
abstract = "Aim: To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site. Patients and Methods: A phase I trial in four dose-escalation steps was planned: total dose ranged between 14 and 20 Gy in a total of four fractions administered twice a day. The dose-limiting toxicity (DLT) was determined as grade 3 or more toxicity occurring during treatment. The MTD obtained was used to plan a phase II trial. Results: A total of 48 patients were treated. In the phase I trial, the 20 Gy dose level was determined to be the MTD. In the phase II trial, the palliative response rate was 82.7{\%}, with a median duration of palliation of 3 months. Conclusion: Short-course accelerated radiotherapy was well tolerated and effective for palliation. These findings may help design future prospective randomized studies.",
keywords = "Head, Neck cancer, Pain, Palliative care, Quality of life, Radiotherapy",
author = "Eleonora Farina and Jenny Capuccini and Gabriella Macchia and Luciana Caravatta and Nguyen, {Nam P.} and Silvia Cammelli and Andrea Farioli and Rambaldi, {Giuseppe Zanirato} and Savino Cilla and Tigeneh Wondemagegnhu and Uddin, {A. F.M.Kamal} and Sumon, {Mostaf{\`a} Aziz} and Domenico Genovesi and Milly Buwenge and Francesco Cellini and Vincenzo Valentini and Francesco Deodato and Morganti, {Alessio G.}",
year = "2018",
month = "4",
day = "1",
doi = "10.21873/anticanres.12491",
language = "English",
volume = "38",
pages = "2409--2414",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer

AU - Farina, Eleonora

AU - Capuccini, Jenny

AU - Macchia, Gabriella

AU - Caravatta, Luciana

AU - Nguyen, Nam P.

AU - Cammelli, Silvia

AU - Farioli, Andrea

AU - Rambaldi, Giuseppe Zanirato

AU - Cilla, Savino

AU - Wondemagegnhu, Tigeneh

AU - Uddin, A. F.M.Kamal

AU - Sumon, Mostafà Aziz

AU - Genovesi, Domenico

AU - Buwenge, Milly

AU - Cellini, Francesco

AU - Valentini, Vincenzo

AU - Deodato, Francesco

AU - Morganti, Alessio G.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Aim: To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site. Patients and Methods: A phase I trial in four dose-escalation steps was planned: total dose ranged between 14 and 20 Gy in a total of four fractions administered twice a day. The dose-limiting toxicity (DLT) was determined as grade 3 or more toxicity occurring during treatment. The MTD obtained was used to plan a phase II trial. Results: A total of 48 patients were treated. In the phase I trial, the 20 Gy dose level was determined to be the MTD. In the phase II trial, the palliative response rate was 82.7%, with a median duration of palliation of 3 months. Conclusion: Short-course accelerated radiotherapy was well tolerated and effective for palliation. These findings may help design future prospective randomized studies.

AB - Aim: To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site. Patients and Methods: A phase I trial in four dose-escalation steps was planned: total dose ranged between 14 and 20 Gy in a total of four fractions administered twice a day. The dose-limiting toxicity (DLT) was determined as grade 3 or more toxicity occurring during treatment. The MTD obtained was used to plan a phase II trial. Results: A total of 48 patients were treated. In the phase I trial, the 20 Gy dose level was determined to be the MTD. In the phase II trial, the palliative response rate was 82.7%, with a median duration of palliation of 3 months. Conclusion: Short-course accelerated radiotherapy was well tolerated and effective for palliation. These findings may help design future prospective randomized studies.

KW - Head

KW - Neck cancer

KW - Pain

KW - Palliative care

KW - Quality of life

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85045109226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045109226&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12491

DO - 10.21873/anticanres.12491

M3 - Article

VL - 38

SP - 2409

EP - 2414

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -